Chargement en cours...
Implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial and associated FDA public safety alert
Recently, the FDA issued a public safety alert, responding to results of the now-published Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities (CARES) trial. CARES showed no significant difference between allopurinol and febuxostat in the primary...
Enregistré dans:
| Publié dans: | Arthritis Rheumatol |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6203619/ https://ncbi.nlm.nih.gov/pubmed/29869840 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40583 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|